Governance Shionogi & Co., Ltd.

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 01:30:00 2026-01-19 EST			5-day change	1st Jan Change
2,840.50 ^JPY	-0.77%		-1.90%	-0.02%

01-15	Jefferies Adjusts Shionogi's Price Target to 3,100 Yen From 2,500 Yen, Keeps at Hold	MT
01-08	Shionogi China receives approval from National Medical Products Administration for cefiderocol for treatment of complicated urinary tract infections	RE

Executive Committee: Shionogi & Co., Ltd.

Manager

Positions heldSince

Isao Teshirogi

66 year

Chief Executive Officer	2022-06-30
President	2008-03-31

John Keller

61 year

Chief Tech/Sci/R&D Officer

2022-06-30

Composition of the Board of Directors: Shionogi & Co., Ltd.

Director

CommitteesSince

Isao Teshirogi

66 year

Nominating Committee	2022-02-28
Compensation Committee Chair	2022-02-28

Keiichi Ando

74 year

Compensation Committee	2017-05-31
Nominating Committee	2017-05-31

Shuichi Okuhara

57 year

Audit Committee

2025-05-31

Kohji Hanasaki

64 year

Audit Committee

2025-05-31

Noriyuki Kishida

65 year

Audit Committee

2025-05-31

Kyoko Hirose

66 year

Director/Board Member	2025-05-31
Independent Dir/Board Member	2025-05-31

Takaoki Fujiwara

73 year

Director/Board Member	2023-05-31
Independent Dir/Board Member	2023-05-31

John Keller

61 year

Director/Board Member

2025-04-30

Fumi Takatsuki

50 year

Director/Board Member	2020-05-31
Independent Dir/Board Member	2020-05-31

Hiroshi Ozaki

75 year

Director/Board Member	2019-05-31
Independent Dir/Board Member	2019-05-31

Latest Appointments: Shionogi & Co., Ltd.

25-10-31	Shionogi & Co., Ltd. Announces Management Appointments	CI
25-02-27	Indivior Parts Ways With CEO as Leadership Shakeup Continues	DJ
22-05-24	Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment	CI
14-09-07	Shionogi & Co., Ltd. Announces Corporate Reorganization; Announces Personnel Reassignment, Effective from October 1, 2014	CI
14-03-25	Shionogi & Co., Ltd. Announces Executive Changes	CI
13-02-25	Shionogi & Co., Ltd. Announces Corporate Re-Organization; Announces Personnel Re-Assignments	CI
12-03-11	Shionogi & Co. Ltd. Announces Executive Changes	CI

More news

Former Officers and Directors: Shionogi & Co., Ltd.

Insider

Positions held

SinceUntil

Yuji Hosogai

Comptroller/Controller/Auditor	2022-06-30	-
Director of Finance/CFO	2022-06-30	-
Investor Relations Contact	2022-06-30	-

Motozo Shiono

Director/Board Member	1984-05-31	2008-03-31
Chairman	2008-03-31	2020-06-22
Corporate Officer/Principal	1999-07-31	2008-03-31

Akio Nomura

Director/Board Member	2009-05-31	2019-06-17
Independent Dir/Board Member	2009-05-31	2019-06-17

Katsuhiko Machida

Director/Board Member	2012-05-31	2016-05-31
Independent Dir/Board Member	2014-06-24	2016-05-31

Yasuhiro Mino

Director/Board Member	2010-01-05	2012-06-26
Corporate Officer/Principal	2010-01-05	2012-06-26

Sapan Shah

Chief Executive Officer	-	2011-04-04
President	-	2011-04-04

Takahiko Baba

Corporate Officer/Principal

2010-12-31

Larry Dillaha

Chief Tech/Sci/R&D Officer

2006-03-31

Teppei Mogi

Director/Board Member	2009-05-31	-
Independent Dir/Board Member	2009-05-31	-

Ikuo Kato

Comptroller/Controller/Auditor	2016-05-31	-
Chief Tech/Sci/R&D Officer	2007-03-31	2016-05-31

Masaaki Takeyasu

Corporate Officer/Principal

1987-12-31

Akira Okamoto

Comptroller/Controller/Auditor	2011-03-31	-
Human Resources Officer	2007-03-31	2011-03-31
Corporate Officer/Principal	2006-03-31	2007-03-31

Takuko Sawada

Director/Board Member	2015-05-31	-
Corporate Officer/Principal	2002-03-31	2022-06-30

Mitsuaki Ohtani

Comptroller/Controller/Auditor

1975-03-31

Sachio Tokaji

Comptroller/Controller/Auditor	2011-07-10	-
Director/Board Member	2010-01-05	2011-07-10
Corporate Officer/Principal	2010-01-05	2011-07-10

Miyuki Hiura

Corporate Officer/Principal

Yasuetsu Imune

Corporate Officer/Principal

Harumi Shimai

Sales & Marketing

Hirofumi Nagadome

Human Resources Officer

Yutaka Hashimoto

Corporate Officer/Principal

Aki Ikehata

General Counsel

Takashi Koide

Public Communications Contact

2014-06-24

Yoshinori Yurugi

Corporate Officer/Principal

Masaki Tomiyama

Corporate Officer/Principal

Yasuyuki Kurokawa

Human Resources Officer	2016-09-30	-
Sales & Marketing	2016-09-30	-

Donna Hackett

Corporate Officer/Principal

Akio Tsubokura

Sales & Marketing

Takayuki Yoshioka

Corporate Officer/Principal

Hiroki Takagi

Public Communications Contact

Yoshihiko Shichino

Public Communications Contact

Toshio Nishi

Corporate Officer/Principal

Kiyoshi Nagata

Corporate Officer/Principal

2011-07-10

Gisaburo Shiono

Founder

Yoshiaki Kamoya

Corporate Officer/Principal

2010-01-05

Masaaki Goshima

Corporate Officer/Principal	2010-01-05	2012-09-02
Sales & Marketing	2012-09-02	-

Shigenobu Mashimo

Corporate Officer/Principal

2010-01-05

Hirosato Kondo

Corporate Officer/Principal

2010-01-05

Ryuichi Kume

Corporate Officer/Principal

2010-01-05

Takuo Fukuda

Corporate Officer/Principal

2010-01-05

Dámaso Molero

Corporate Officer/Principal

Akira Kato

Chief Executive Officer	-	-
President	-	-

Satoshi Komatsu

Comptroller/Controller/Auditor

2010-01-05

Age distribution of managers

Parity Men Women

Male	11
Female	2

Of which Executive Committee

Male	2
Female	0

Of which Directors

Male	8
Female	2

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

Employees

4,955

Sector

Pharmaceuticals

Calendar

01-29 - Q3 2025 Earnings Release

More about the company